GlassScriptPhysician profile
Paul C Boulware
NPI 1609912146
$6,644.44
in general payments reported to CMS, 2019-2025
29 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.65 · 2020: $94.01 · 2021: $64.90 · 2022: $495 · 2023: $1,939 · 2024: $2,086 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,881 · Education: $71.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,880.74 |
| Education | $71.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.79 | 2021-2025 | Vraylar |
| Alkermes, INC. | $691.68 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $577.68 | 2020-2025 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $557.57 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $536.18 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $495.95 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $422.92 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $331.94 | 2023-2025 | Ingrezza |
| Tris Pharma INC | $285.33 | 2023-2025 | Dyanavel Xr |
| Braeburn INC. | $251.22 | 2024-2025 | Brixadi |
| Axsome Therapeutics, INC. | $228.37 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $219.55 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $196.44 | 2022-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $122.08 | 2022-2023 | Qelbree |
| Corium, LLC | $120.56 | 2022-2025 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $103.74 | 2023-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $66.94 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $62.96 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Collegium Pharmaceutical, INC. | $38.21 | 2025 | Jornay Pm |
| Orexo US, INC. | $37.75 | 2023-2025 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $29.14 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $24.17 | 2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $20.59 | 2019 | |
| Tempus Ai, INC | $19.19 | 2024 | Tempus Pixel |
| Allergan, INC. | $19.18 | 2020 | |
| Boston Scientific Corporation | $15.73 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.77 | 2025 | Relexxii |
| Neos Therapeutics, LP | $14.34 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $13.47 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Boulware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.